Table 2

DDR inhibitors used in tumor combination chemotherapy

Target	Inhibitors			Pathway	Combination
ATM	AZD0156^b M4076^b KU60019^b	AZD1390^b KU55933^c	M3541^b KU59403^c	HR NHEJ	Irinotecan Olaparib
ATR	ART0380^b AZD6738^b Berzosertib^b DN020198^b HRS2398^b M6620^b Tuvusertib^b	ATG-018^b AZ20^c Camonsertib^b Elimusertib^b IMP9064^b RP-3500^b	ATRN-119^b BAY1895344^b Ceralasertib^b Gartisertib^b M4344^b SC0245^b	HR	Carboplatin Cisplatin Gemcitabine Irinotecan Niraparib Olaparib Topotecan Veliparib
CHK1/2	AZD7762^b LY2603618^b PF-00477736^b UCN-01^b	GDC-0575^b LY2880070^b Prexasertib^b	GNE-323^c MK-8776^b SRA737^b	HR NHEJ	Cisplatin Gemcitabine Irinotecan Olaparib
DNA-PKcs	AZD7648^b CC-115^b M9831^b Peposertib^b	BY101801^b LY294002^c Nu7026^c Samotolisib^b	BY101298^b M3814^b NU7441^c XRD-0394^b	NHEJ	Capecitabine Doxorubicin Etoposide
FEN1	FEN1-IN-1^c FEN1-IN-4^c FEN1-IN-7^c	FEN1-IN-2^c FEN1-IN-5^c FEN1-IN-SC13^c	FEN1-IN-3^c FEN1-IN-6^c		Camptothecin Cisplatin Olaparib
MRE11	Antitumor agent-96^c PFM01^c	Mirin^c PFM39^c	PFM03^c	HR	Carboplatin Cisplatin Doxorubicin Olaparib
OGG1	OGG1-IN-08^c	TH5487^c	SU0268^c	BER	Olaparib
PARP	ABT-767^b AZD9574^b CK-102^b Fuzuloparib^a HWH340^b NMS-293^b RP12146^b SC10914^b Stenoparib^b TSL1502^b	AMXI-5001^b Basroparib^b CVL218^b HS-10502^b Nesuparib^b Olaparib^a Rucaparib^a Senaparib^b Talazoparib^a Veliparib^b	AZD-2461^b BMN-673^b E7016^b HTMC0435^b Niraparib^a Pamiparib^b Saruparib^b Simmiparib^b TQB3823^b Venadaparib^b	BER NHEJ	Cisplatin Irinotecan Temozolomide
PARG	COH34^c ETX-19477^b PDD00017272^c	DAT-2645^b IDE161^b PDD00017273^c	Ethacridine^c JA2131^c PDD00031705^c	BER NHEJ	Olaparib
Polθ	ART4215^b GSK4524101^c RP-6685^c	ART558^c Novobiocin^b ZM-2311^c	ART6043^b RP-3467^b	MMEJ	Niraparib Olaparib Talazoparib
RAD51	B02^c RI-1^c Chicago Skye Blue^c	DIDS^c RI-2^c	IBR2^c RS-1^c	HR	Cisplatin Mitomycin C Olaparib
RAD52	AICAR^c NP-004255^c	D-103^c 6-Hydroxy-DOPA^c	D-G23^c	HR	Cisplatin Olaparib
REV1	JH-RE-06^c			TLS	Cisplatin
RPA	HAMNO^c JC-229^c	TDRL-551^c NSC15520^c	ML367^c Anti-osteoporosis agent-1^c		Cisplatin Etoposide Olaparib
USP1	C527^c ML-323^c TNG348^c	I-138^c SJB3-019A^c	KSQ-4279^b SJB2-043^c	TLS FA	Cisplatin Olaparib
USP7	GNE-6640^c HBX-28258^c P22077^c XL177A^c YCH3124^c	GNE-6776^c HBX41108^c USP7-055^c XL188^c	HBX19818^c P005091^c USP7-797^c YCH2823^c	HR	Cisplatin Etoposide Olaparib
WEE1	AZD1775^b Debio0123^b SC0191^b	Adavosertib^b IMP7068^b SY-4835^b	Azenosertib^b PD0166285^c ZN-c3^b	G2/M checkpoint	Carboplatin Cisplatin Doxorubicin Gemcitabine Olaparib Paclitaxel
WRN	H3B-968^c NSC19630^c	HRO761^b NSC617145^c	NCGC00029283^c VVD-214^c	HR	Irinotecan Mitomycin C Olaparib

Stage of DDR inhibitors: ^aapproved, ^bclinical, ^cpreclinical.

BER, base excision repair; FA, Fanconi anemia; FEN1, flap endonuclease-1; MMEJ, microhomology-mediated end joining; OGG1, 8-oxoguanine DNA glycosylase; PARG, poly(ADP-ribose) glycohydrolase; REV1, REV1 DNA directed polymerase; RPA, replication protein A; USP1, ubiquitin-specific protease 1; USP7, ubiquitin-specific protease 7; WEE1, WEE1 G2 checkpoint kinase; WRN, Werner syndrome RecQ helicase.